Loading patent…
AssigneeBecton, Dickinson and Company
InventorsRichard M. Ivey, Thomas M. Gentle, Richard L. Moore, Michael L. Towns, Nicholas Bachur, Robert W. Rosenstein, James G. Nadeau, Paul E. Goldenbaum, Song Shi, Donald Copertino, James Garrett, Gregory Tice, Gary Siuzdak, Elizabeth Want, Zhouxin Shen
Estimating the term…
Mass spectrometry techniques for determining the status of sepsis in an individual are provided. A biomarker profile resolved from a biological sample, taken from the individual, using a mass spectrometry technique is compared to a reference biomarker profile. A single such comparison classifies the individual as belonging to or not belonging to a reference population. The individual's biomarker profile and the reference biomarker profile comprise a plurality of ions each having a mass-to-charge ratio of about 100 Daltons to about 1000 Daltons. The plurality of ions can be detected by electrospray ionization mass spectrometry in positive mode. The comparison uses a decision rule, such as a classification tree, that determines the status of sepsis in the individual without requiring knowledge of the identity of the biomarkers in the biomarker profile from the individual and without requiring knowledge of the identity of the biomarkers in the reference biomarker profile.
A method of determining the status of sepsis in an individual using mass spectrometry, comprising:
A method of predicting the onset of sepsis in an individual, comprising:
A biomarker profile comprising at least two features that contribute to the classification of an individual as belonging to a reference population with an accuracy of at least about 60%, based on a comparison with a reference profile of the reference population, wherein the reference population is selected from the group consisting of a normal reference population, a SIRS-positive reference population, an infected/SIRS-negative reference population, a sepsis-positive reference population, and a reference population at a stage in the progression of sepsis, and wherein the biomarker profile is resolved from a first biological sample, taken from the individual, using a mass spectrometry technique.
Dependencies are inferred from the claim text.